AgomAb screens as a high-asymmetry biotech with 120% analyst-target upside, but quality metrics sit below the engine's investable floor and momentum is only marginally positive, so the exit-position call stands despite the headline valuation gap.
Thesis pillars
- Value Trap Leverage Margin→Stable
- Asymmetric Upside To Target→Stable
- Sub Floor Business Quality→Stable
- +2 more pillars — see the Why tab for full reasoning
AgomAb Therapeutics NV (AGMB) Stock Analysis
Healthcare · Biotechnology
Sell if holding. Engine safety override at $9.09: Quality below floor (2.5 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.2/10. Specifically: Below-average business quality; Negative price momentum.
AgomAb Therapeutics NV, a clinical-stage biopharmaceutical company, develops novel disease-modifying therapies for immunology and inflammatory diseases in the United States. The company's product pipeline includes Ontunisertib (AGMB-129), an oral gastrointestinal-restricted... Read more
Sell if holding. Engine safety override at $9.09: Quality below floor (2.5 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.2/10. Specifically: Below-average business quality; Negative price momentum. Chart setup: No clear chart pattern; technical signals are mixed. Score 5.2/10, moderate confidence.
Passes 5/7 gates (clean insider activity, no SEC red flags, earnings proximity no date, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum. Suitability: speculative.
Recent developments
updated 2026-10-12Recent Developments — AgomAb Therapeutics NV
Latest news
- NEWS Agomab Therapeutics To Present Open-Label Extension Data For Ontunisertib In Fibrostenosing Crohn's Disease At UEG Week — benzinga Oct 8, 2026 positive
- NEWS 12 Health Care Stocks Moving In Thursday's After-Market Session — benzinga Oct 1, 2026 neutral
- NEWS Agomab Therapeutics Experimental Drug Delivers Sustained Disease Control in Long-Term Crohn's Disease Trial — benzinga Oct 1, 2026 positive
- NEWS 12 Health Care Stocks Moving In Thursday's Intraday Session — benzinga Oct 1, 2026 neutral
- NEWS Agomab Therapeutics Announces Results From 48-Week OLE Portion Of Its Phase 2A STENOVA Trial Evaluating Ontunisertib In — benzinga Oct 1, 2026 positive
Generated 2026-10-13T11:47:14Z.
Thesis
Key Metrics
Quality Signals
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
2 floor-breakers
Quality below the gate floor. Component breakdown shows what dragged the score down.static
Price action weak — below key moving averages, no momentum carry. Needs a base before trend-continuation setups apply.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $9.09: Quality below floor (2.5 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.2/10. Specifically: Below-average business quality; Negative price momentum. Chart setup: No clear chart pattern; technical signals are mixed. Prior stop was $8.45. Score 5.2/10, moderate confidence.
Take-profit target: $12.73 (+40.0% upside). Prior stop was $8.45. Stop-loss: $8.45.
DATA_ISSUE: analyst_target_implausible (raw $37.67 vs price $9.09 — ratio 4.1×). Rejected, falling back to technical TP.; Quality below floor (2.5 < 4.0); Value-trap signals (2/5): Margin compression (op margin 3.2%), Material insider selling (9 sells, 1.11% of cap).
AgomAb Therapeutics NV trades at a P/E of N/A (forward -4.4). TrendMatrix value score: 5.0/10. Verdict: Sell.
14 analysts cover AGMB with a consensus score of 4.2/5. Average price target: $38.
What does AgomAb Therapeutics NV do?AgomAb Therapeutics NV, a clinical-stage biopharmaceutical company, develops novel disease-modifying therapies for...
AgomAb Therapeutics NV, a clinical-stage biopharmaceutical company, develops novel disease-modifying therapies for immunology and inflammatory diseases in the United States. The company's product pipeline includes Ontunisertib (AGMB-129), an oral gastrointestinal-restricted small molecule inhibitor of ALK5 or TGFßR1 for the treatment of Fibrostenosing Crohn's disease, which is in Phase 2a clinical trials; and AGMB-447, an inhaled small molecule inhibitor of ALK5 or TGFßR1 for the treatment of idiopathic pulmonary fibrosis that is in Phase 1 clinical trials. It also develops AGMB-101, a HGF-mimetic monoclonal antibody that acts through agonism or stimulation of the MET receptor and has demonstrated antifibrotic and regenerative activity in preclinical models. The company was incorporated in 2017 and is headquartered in Antwerp, Belgium.